In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Oxford Nanopore’s chief executive Gordon Sanghera plans to step down next year, as the genetic sequencing tools company once seen as a promising win for the London market struggled to live up to ...

There's been an all-out push by the drug regulators and media to get every adult and child on Ozempic, a drug which causes temporary weight loss and harms the majority of recipients. Here, two leading ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

This FTSE 100 stock could be on the verge of stealing enormous chunks of market share from some of the largest pharmaceutical ...